Posted by Michael Wonder on 06 Jun 2025
MSD Korea wins coverage boost for transplant infection drug Prevymis
4 June 2025 - MSD Korea has won expanded reimbursement for Prevymis (letermovir), extending coverage from 100 to 200 days post-transplant in high risk adults who receive donor stem cell transplants and carry cytomegalovirus (CMV).
The updated policy, which the National Health Insurance Service implemented on Sunday, applies to CMV seropositive patients undergoing allogeneic haematopoietic stem cell transplantation or donor derived bone marrow transplants.
